Lachkar Floriane, Papaioannou Alexandra, Ferré Pascal, Foufelle Fabienne
Centre de recherches des Cordeliers, UMRS1128 Inserm, Sorbonne Université, 15 rue de l'École de Médecine, 75270 Paris cedex 06, France.
Biol Aujourdhui. 2020;214(1-2):15-23. doi: 10.1051/jbio/2020007. Epub 2020 Aug 10.
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent pathology associated with obesity. It encompasses a spectrum of hepatic disorders ranging from steatosis to non-alcoholic steatohepatitis (NASH), which may lead to cirrhosis and hepatocellular carcinoma (HCC). Endoplasmic reticulum (ER) stress has been widely involved to drive in NAFLD progression through the activation of the unfolded protein response (UPR). While transient UPR activation can boost hepatic ER functions, its continuous activation upon a chronic ER stress contributes to lipid accumulation, inflammation and hepatocyte death, which are determinant factors for the progression to more severe stages. The aim of this review is to describe the mechanisms through which the UPR can take part in the transition from a healthy to a diseased liver and to report on possible ways of pharmacological manipulation against these pathological mechanisms.
非酒精性脂肪性肝病(NAFLD)是一种与肥胖相关的高度普遍的病症。它涵盖了一系列肝脏疾病,从脂肪变性到非酒精性脂肪性肝炎(NASH),后者可能导致肝硬化和肝细胞癌(HCC)。内质网(ER)应激已广泛参与通过激活未折叠蛋白反应(UPR)来推动NAFLD的进展。虽然短暂的UPR激活可以增强肝脏ER功能,但其在慢性ER应激下的持续激活会导致脂质积累、炎症和肝细胞死亡,这些是疾病进展到更严重阶段的决定性因素。本综述的目的是描述UPR参与从健康肝脏向患病肝脏转变的机制,并报告针对这些病理机制进行药物操纵的可能方法。